Your browser doesn't support javascript.
loading
Transplantation for metastatic liver disease.
Clift, Ashley Kieran; Hagness, Morten; Lehmann, Kuno; Rosen, Charles B; Adam, Rene; Mazzaferro, Vincenzo; Frilling, Andrea.
Affiliation
  • Clift AK; Cancer Research UK Oxford Centre, University of Oxford, United Kingdom; Department of Surgery & Cancer, Imperial College London, United Kingdom.
  • Hagness M; Department of Transplantation Medicine, Oslo University Hospital, Oslo, Norway.
  • Lehmann K; Department of Surgery and Transplantation, University Hospital and University of Zurich, Zurich, Switzerland.
  • Rosen CB; Division of Transplantation Surgery, Department of Surgery, Mayo Clinic, Rochester, United States; Research Unit of Chronotherapy, Cancers and Transplantation, AP-HP Paul Brousse Hospital, Paris-Saclay University, Villejuif, France.
  • Adam R; Research Unit of Chronotherapy, Cancers and Transplantation, AP-HP Paul Brousse Hospital, Paris-Saclay University, Villejuif, France.
  • Mazzaferro V; HPB Surgery and Liver Transplantation, Fondazione IRCCS Istituto Nazionale Tumori di Milano, Milan, Italy.
  • Frilling A; Department of Surgery & Cancer, Imperial College London, United Kingdom. Electronic address: a.frilling@imperial.ac.uk.
J Hepatol ; 78(6): 1137-1146, 2023 06.
Article in En | MEDLINE | ID: mdl-37208101
ABSTRACT
The liver is a common site of metastases from many cancers, particularly those originating in the gastrointestinal tract. Liver transplantation is an uncommonly used but promising and at times controversial treatment option for neuroendocrine and colorectal liver metastases. Transplantation with meticulous patient selection has been associated with excellent long-term outcomes in individuals with neuroendocrine liver metastases, but questions remain regarding the role of transplantation in those who could also be eligible for hepatectomy, the role of neoadjuvant/adjuvant treatments in minimising recurrence, and the optimal timing of the procedure. A prospective pilot study of liver transplantation for unresectable colorectal liver metastases that reported a 5-year overall survival rate of 60% reinvigorated interest in this area following initially dismal outcomes. This has been followed by larger studies, and prospective trials are ongoing to quantify the potential benefits of liver transplantation over palliative chemotherapy. This review provides a critical summary of currently available knowledge on liver transplantation for neuroendocrine and colorectal liver metastases, and highlights avenues for further study to address gaps in the evidence base.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Colorectal Neoplasms / Liver Neoplasms Type of study: Observational_studies / Risk_factors_studies Limits: Humans Language: En Journal: J Hepatol Journal subject: GASTROENTEROLOGIA Year: 2023 Type: Article Affiliation country: United kingdom

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Colorectal Neoplasms / Liver Neoplasms Type of study: Observational_studies / Risk_factors_studies Limits: Humans Language: En Journal: J Hepatol Journal subject: GASTROENTEROLOGIA Year: 2023 Type: Article Affiliation country: United kingdom